Wait, we have a special
offer for you!

Click the button below to get your discount.

Get my coupon now No thanks, I'd like to pay full price

Use coupon code at checkout:


Use my coupon

Alhemo (Concizumab)

Prescription requiredOnly Available By Prescription
What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.


Alhemo, also known as concizumab, is a biological treatment for hemophilia B, a blood disorder characterized by improper clotting leading to excessive bleeding. Symptoms of this condition can include unexplained bleeding, blood in the urine or stool, large or deep bruises, and indications of severe bleeds.

Alhemo functions by binding to the protein TFPI, which normally inhibits excessive blood clot formation. By binding to TFPI, Alhemo blocks its function, thereby enhancing blood clotting and reducing excessive bleeding. Before you buy Concizumab novo nordisk, it is crucial that you talk to your healthcare provider about its potential side effects and effectiveness.

Fact Table
Formula C6476H9972N1728O2048S52
License FDA Approved
Bioavailability Not Available
Legal status Prescription Only
Chemical Name Concizumab
Elimination half-life Approx. 19 days
Dosage (Strength) 30 mg/ml injection
Pregnancy Use with Caution
Brands Alhemo
Protein binding Unknown
PubChem CID Not Available
MedlinePlus Not Listed
ChEBI Not Available
ATC code B02BD14
DrugBank Not Available
KEGG Not Available
Routes of administration Subcutaneous

Buy Alhemo (Concizumab) online from online Canadian Pharmacy |


Alhemo is available in the following dosages:

  • 15 mg
  • 60 mg
  • 150 mg
  • 300 mg

The medication is administered according to a schedule determined by your doctor. After four weeks of treatment, your doctor will assess Alhemo levels in your blood and adjust the dosage as necessary.


The active component of Alhemo is concizumab.


Alhemo concizumab may lead to serious blood clots, potentially causing permanent damage or death. Inform your doctor if you have a personal or family history of blood clots. Ensure your doctor or pharmacist explains the signs and symptoms of blood clots and monitors you during treatment.

Alhemo is not recommended for patients under 12 years old or for use during pregnancy. If there is a possibility of becoming pregnant while on Alhemo, use effective birth control during treatment and for seven weeks after completion. If you miss a dose, consult your doctor or pharmacist for guidance.


Common interactions with Alhemo include:

Activated prothrombin complex concentrates (PCC)

Recombinant FVIIa (rFVIIa)



Side Effects

Common side effects of Alhemo include:

  • Allergic reactions (hypersensitivity)
  • Blood clots
  • Fever
  • Headache
  • Increased levels of blood clotting components (fibrin D dimer and prothrombin fragment 1.2)
  • Infections

Frequently Asked Questions about Concizumab

What is concizumab?

Concizumab is a monoclonal antibody used in the treatment of hemophilia. It is designed to prevent bleeding episodes in patients with hemophilia A and hemophilia B, particularly those who have developed inhibitors against factor VIII or IX, which are standard treatments for these conditions.

What is the mechanism of action of concizumab?

The mechanism of action of concizumab involves binding to tissue factor pathway inhibitor (TFPI). By inhibiting TFPI, concizumab enhances the generation of thrombin, which is crucial for blood clot formation. This helps to control bleeding in hemophilia patients, even in the presence of inhibitors to standard treatments.

What is the route of administration for concizumab?

Concizumab is administered via subcutaneous injection. This route allows the medication to be absorbed slowly and steadily into the bloodstream, providing sustained therapeutic effects.

What is the half-life of concizumab?

The half-life of concizumab varies based on individual patient factors but typically ranges from 14 to 26 days. This relatively long half-life supports less frequent dosing schedules, which can be advantageous for patient compliance and convenience.

How does concizumab work?

Concizumab works by inhibiting tissue factor pathway inhibitor (TFPI). By blocking TFPI, concizumab promotes the generation of thrombin, an enzyme essential for blood clotting. This action helps to prevent and control bleeding episodes in patients with hemophilia, particularly those with inhibitors to factor VIII or IX.